Join
Live feed
·
PRReleasevia Quantisnow
Oragenics Inc. logo

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

ByQuantisnow·Wall Street's wire, on your screen.
OGEN· Oragenics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OGEN (Oragenics Inc.) and more on Quantisnow.